GANX

Gain Therapeutics, Inc. GANX

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.2M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Top Institutional Holders

as of Q2 2026
$17.40M total
MARSHALL WACE, LLP
$3.90M+8.7%
Potomac Capital Management, Inc.
$1.92M-6.2%
GSA CAPITAL PARTNERS LLP
$1.28M+102.3%
Cambridge Investment Research Advisors, Inc.
$1.15M0.0%
DME Capital Management, LP
$1.15M0.0%
JONES FINANCIAL COMPANIES LLLP
$1.07M-3.6%
VANGUARD CAPITAL MANAGEMENT LLC
$974.9K+20.1%
GEODE CAPITAL MANAGEMENT, LLC
$921.4K+1.4%
BlackRock, Inc.
$558.2K+22.2%
VANGUARD FIDUCIARY TRUST CO
$470.0K+0.7%
UBS Group AG
$436.5K-2.5%
Stratos Wealth Partners, LTD.
$406.0K+52.0%
Cresset Asset Management, LLC
$324.8K0.0%
STATE STREET CORP
$319.8K0.0%
CITADEL ADVISORS LLC
$313.7K+520.6%
Squarepoint Ops LLC
$276.8KNew
MORGAN STANLEY
$255.7K-9.8%
LPL Financial LLC
$238.0K+12.5%
NORTHERN TRUST CORP
$196.9K-14.9%
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$158.8K-81.9%
COMMONWEALTH EQUITY SERVICES, LLC
$118.7K+96.8%
JANE STREET GROUP, LLC
$112.9K-74.4%
XTX Topco Ltd
$112.2KNew
PRELUDE CAPITAL MANAGEMENT, LLC
$72.7K0.0%
BENEDICT FINANCIAL ADVISORS INC
$71.0K+125.8%
See all 50 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

Debt/Equity

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/GANX

Earnings Per Share

13fpro.ai/company/GANX

Loading ratio trend…

GANX key financials by period

Reported revenue, net income and operating margin by fiscal year, from Gain Therapeutics, Inc.'s annual filings on SEC EDGAR.

Gain Therapeutics, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2023$55.2K$-22.3M—
FY 2022$140.1K$-17.6M—
FY 2021$165.0K$-13.9M—
FY 2020$28.9K$-3.6M—
Source: GANX filings on SEC EDGAR →

GANX insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Gain Therapeutics, Inc. (GANX): stock profile, AI score and financials

Gain Therapeutics, Inc. (GANX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. GANX is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.2m in revenue and is scored on the micro-cap board instead. Top institutional holders of GANX by reported 13-F value include MARSHALL WACE, LLP, Potomac Capital Management, GSA CAPITAL PARTNERS LLP, based on the most recent SEC filings. GANX trades on the Nasdaq exchange and files with the SEC under CIK 1819411. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GANX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Gain Therapeutics, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1819411 →